For advanced HR-positive, HER2-negative breast cancer, first-line treatment typically consists of ET combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) [27,28,29,30,31,32]. Here, ERBB2 is linked to breast cancer.